Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. by Hao, Junwei et al.
UCLA
UCLA Previously Published Works
Title
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS 
autoimmune pathology.
Permalink
https://escholarship.org/uc/item/9z7418n5
Journal
The Journal of experimental medicine, 207(9)
ISSN
0022-1007
Authors
Hao, Junwei
Liu, Ruolan
Piao, Wenhua
et al.
Publication Date
2010-08-09
DOI
10.1084/jem.20092749
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Article
The Rockefeller University Press $30.00
J. Exp. Med. Vol. 207 No. 9 1907-1921
www.jem.org/cgi/doi/10.1084/jem.20092749
1907
Inflammatory and immune responses within 
the central nervous system (CNS) significantly 
affect the clinical presentation and outcome 
of brain disorders, including stroke, trauma, 
Alzheimer’s disease, Parkinson’s disease, epi­
lepsy, encephalomyelitis, and multiple sclerosis 
(MS; Weiner and Selkoe, 2002). In the case of 
MS and its animal model experimental auto­
immune encephalomyelitis (EAE), a classical 
inflammatory disease characterized by cellular 
influx, demyelination, and axonal damage of 
the CNS, initiation of disease is controlled by 
an interplay between cells of the innate and 
adaptive immune systems (Steinman, 1996; 
Wekerle, 1998). NK cells are an important cell 
subset of the innate immune system represented 
by large granular lymphocytes that respond 
rapidly to a variety of insults with cytolytic ac­
tivity and cytokine secretion (Kärre et al., 1986; 
Biron et al., 1999; Yokoyama and Plougastel, 
2003; Raulet, 2004; Lanier, 2008). Recently, 
there has been a growing understanding of NK 
cells, particularly with regard to their roles in 
autoimmunity in the joints, pancreas, and CNS 
(French and Yokoyama, 2004; Shi and Van 
Kaer, 2006; Wu et al., 2007; Feuerer et al., 
2009). Mechanisms by which NK cells could 
have an impact on autoimmune responses in­
clude a rapid cytokine release by NK cells be­
fore autoreactive helper T cell differentiation 
and modulation of interactions between auto­
reactive T cells, B cells, and APCs (Chambers 
et al., 1996; Shi et al., 2000; Martín­Fontecha 
et al., 2004; Laouar et al., 2005). However, 
much of this evidence is derived from studying 
peripheral lymphoid organs. Whether NK cells 
can act in target organs of autoimmunity such 
as the CNS has not yet been investigated.
The manifestations of CNS disease, such as 
MS and EAE, require the homing of myelin­ 
reactive T cells to the CNS, where T cells 
undergo reactivation, further differentiation, and 
expansion. The spectrum of APCs, antigens, 
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Natural killer (NK) cells of the innate immune system can profoundly impact the develop-
ment of adaptive immune responses. Inflammatory and autoimmune responses in anatomical 
locations such as the central nervous system (CNS) differ substantially from those found in 
peripheral organs. We show in a mouse model of multiple sclerosis that NK cell enrichment 
results in disease amelioration, whereas selective blockade of NK cell homing to the CNS 
results in disease exacerbation. Importantly, the effects of NK cells on CNS pathology were 
dependent on the activity of CNS-resident, but not peripheral, NK cells. This activity of 
CNS-resident NK cells involved interactions with microglia and suppression of myelin-
reactive Th17 cells. Our studies suggest an organ-specific activity of NK cells on the magni-
tude of CNS inflammation, providing potential new targets for therapeutic intervention.
© 2010 Hao et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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(clone PK136) dramatically enhanced EAE severity (Zhang 
et al., 1997; Xu et al., 2005). We confirmed these findings and 
verified that disease exacerbation was caused by the removal 
of NK cells rather than NKT cells (Fig. S2). Pathologically, the 
mice treated with anti­NK1.1 mAb exhibited pronounced cel­
lular infiltrates, inflammation, and demyelination, as indicated 
by immunohistochemical staining, bioluminescence imaging, 
and high­field MRI, respectively (Fig. 1, A–C).
We considered two possibilities for the exaggerated CNS 
disease observed in MOG­immunized mice systemically de­
pleted of NK cells: (1) enhanced pathogenic T cell infiltration 
from the periphery to the CNS, or (2) attenuated suppressive 
effects of NK cells on pathogenic T cells within the CNS. 
To distinguish between these two possibilities, we used a model 
of selective NK cell deficiency in the CNS. We used mice in 
which the chemokine receptor Cx3cr1 gene was replaced with 
a cDNA encoding GFP (Jung et al., 2000). We previously 
demonstrated that CX3CR1 is responsible for recruiting 
NK cells to the inflamed CNS in mice with EAE (Huang 
et al., 2006) and that Cx3cr1GFP/GFP (Cx3cr1/) mice exhibit 
a selective deficit in NK cell homing to the CNS, whereas 
NK cells in other organs are not affected (Huang et al., 2006). 
Pathologically, the MOG­primed Cx3cr1/ mice had fre­
quent hemorrhagic brain and spinal cord lesions (Huang et al., 
2006). Increased inflammation and disease activity were fur­
ther illustrated by neuroimaging (Fig.1, B and C).
Collectively, these results suggest that NK cell depletion from 
all organ systems augments the magnitude of CNS inflammation 
and pathology. The finding that Cx3cr1/ mice with reduced 
and neuroimmune interactions within the CNS are unique 
(Shi and Ransohoff, 2010), and the outcome of an immune 
response cannot be predicted solely by the events that occurred 
in the periphery. NK cells readily home to the CNS under an 
array of pathological circumstances (Shi and Ransohoff, 2010). 
It is not known whether these NK cells are simply passive 
migrants or actively participate in the CNS pathogenesis.
In this paper, we investigated the role of NK cells in the 
CNS in shaping autoimmunity and pathology. Our findings 
have revealed a critical role of CNS­resident NK cells in con­
trolling the magnitude of CNS inflammation. This observation 
could be exploited for therapeutic intervention in CNS disease.
RESULTS
Peripheral versus CNS-resident NK cells in shaping CNS 
inflammation and pathology
Studies of NK cell function in vivo have often been challeng­
ing because of the unavailability of mice that selectively lack 
NK cells (Yokoyama and Plougastel, 2003; Shi and Van Kaer, 
2006). To overcome this limitation, we have combined sev­
eral approaches, including NK cell–depleting mAb, interrup­
tion of NK cell homing, and NK cell enrichment (Fig. S1).
To dissect the role of NK cells in the development of in­
flammatory and autoimmune responses in the CNS, we im­
munized C57BL/6 (B6) mice with myelin oligodendrocyte 
glycoprotein (MOG) peptide, which produces a monophasic 
neurological deficit resembling a form of human MS known as 
acute disseminated encephalomyelitis. Previously, it was dem­
onstrated that depletion of NK1.1+ cells by anti­NK1.1 mAb 
Figure 1. NK cells control the magnitude of CNS inflammation. (A) Microscopy of CNS sections from MOG-immunized mice that received control 
IgG or anti-NK1.1 mAb. H&E (left) and luxol fast blue (right) staining reveals the intensity of cell infiltration and myelin integrity, respectively. Graphs 
show quantified data. Bars, 100 µm. (B) Visualization and quantification of brain inflammation by in vivo bioluminescence imaging. Graphs show quanti-
fied data. (C) T2-weighted periventricular images were obtained with a 7T MR scanner. Arrows indicate focal lesions located around the lateral ventricle 
and increased signal intensity on T2-weighted lesions. Pathology and imaging experiments were conducted in groups of mice (n = 4–8) between 15 and 
20 d after immunization. P-values were determined by a Student’s t test. Data are representative of two independent experiments (mean ± SEM).
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isolates divided four­ to sixfold more frequently in NK cell–
depleted mice than in control mice (Fig. 2 A). As expected, 
lymph node CD4+ T cells from Cx3cr1/ mice proliferated 
at a similar magnitude as those from WT mice, whereas 
CNS­derived Cx3cr1/ CD4+ T cells proliferated more vigo­
rously (Fig. 2 A). These results indicate that NK cells suppress 
CD4+ T cell proliferation and this suppression is more pro­
nounced in the CNS than in peripheral organs.
Next, we assessed the impact of NK cell depletion or their 
failure to home to the CNS on the phenotype of CD4+ T cells. 
Depletion of NK cells reduced MOG­reactive IFN­–producing 
Th1 cell responses in lymph node but not the CNS (Fig. 2 B). 
In contrast, MOG­reactive CD4+ Th17 cell responses were 
increased three­ to fivefold in the CNS of NK cell–depleted 
mice. Importantly, the enhancement of Th17 cell responses was 
almost exclusive to CD4+ T cells in the CNS (Fig. 2 B). Quan­
titative (q) RT­PCR for il­17a transcripts using sorted CD4+  
T cells confirmed this finding (Fig. 2 C). These results of NK 
cell depletion were mirrored by an increase of Th17 phenotype 
cells in Cx3cr1/ mice (Fig. 2, B and C). The global levels of 
IL­17 and IFN­ quantified using lymph node, brain, and spi­
nal cord homogenates were consistent with those observed 
for CD4+ T cells (Fig. S3). Depletion of NK cells also led to en­
hanced proliferation of CD8+ T cells in lymph nodes, but such 
effects were absent in the CNS (Fig. S4, A and B). In addition, 
the frequency of IL­17+ CD8+ T cells was minimal and did not 
change significantly upon NK cell depletion (Fig. S4 C). Thus, 
suppression of myelin­reactive CD4+ Th17 cells by NK cells is 
largely restricted to the CNS compartment.
CNS­infiltrating NK cells but intact peripheral NK cells exhib­
ited similar clinical and pathological features to NK cell–depleted 
animals suggests that CNS NK cells are crucial in this process.
Suppression of myelin-reactive Th17 cells by NK cells is 
restricted to the CNS
Autoreactive T cells, particularly the CD4+ subset, home to 
the CNS, reencounter myelin antigens in this location and 
undergo reactivation and further expansion. This process is 
believed to be a prerequisite step for the expression of disease 
in EAE and perhaps in MS. Therefore, we investigated how 
NK cell depletion, or failure to home to the CNS, might in­
fluence the capacity of CD4+ T cells to proliferate and further 
differentiate into Th1 or Th17 cells. Lymph node (or splenic) 
CD4+ T cells from mice treated with anti­NK1.1 mAb di­
vided 1.5­fold more frequently than CD4+ T cells from con­
trol mice (Fig. 2 A and not depicted). CD4+ T cells from CNS 
Figure 2. Influence of NK cell depletion or impaired homing of  
NK cells to the CNS on myelin-reactive Th1 and Th17 cell responses 
in the periphery and the CNS. Groups of mice (receiving mouse IgG  
or anti-NK1.1 mAb, and Cx3cr1+/+ or Cx3cr1/) were immunized with 
MOG/CFA/PT and sacrificed between days 12 and 20 after immunization. 
Lymph node (LN), spleen, and CNS cells were isolated. (A) Expansion of CD4+ 
T cells from lymphoid organs or CNS was assessed by CFSE dilution or BrdU 
incorporation assay, respectively. (B) Lymphoid or CNS cells were restimu-
lated with MOG overnight, and IFN-– and IL-17–expressing CD4+ T cells 
were measured by intracellular staining. (C) Il-17a mRNA of sorted CD4+  
T cells was measured by qRT-PCR. Data are representative of four indepen-
dent experiments (n = 18–25/group). Error bars represent the means ± SEM. 
P = 0.007 and 0.006 for IL-17–expressing CD4+ cells (Student’s t test).
Figure 3. Frequencies and phenotype of NK cells in MOG- 
immunized mice treated with IL-2 complexes. Upon EAE induction 
with MOG, B6 mice were treated with control IgG, IL-2, anti–IL-2 mAb 
(S4B6), or a combination of IL-2 and anti–IL-2 mAb (IL-2 C) i.p. as indi-
cated in Materials and methods. Single cell suspensions were prepared 
from the spleen and CNS of mice on days 12–20, and the frequencies and 
phenotypes of mononuclear cells were analyzed by FACS. (A) The frequen-
cies of NK and NKT cells in the periphery and CNS. (B) Expression of NKG2A 
on NK cells. (C) Production of IFN- by NK cells. P-values were determined 
by a Student’s t test. The dot plots are representative of three separate 
experiments (n = 5–15/group). Error bars represent the means ± SEM.
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affinity IL­2 receptors and stimulate the proliferation of 
memory phenotype CD8+ T cells and NK cells (Boyman 
et al., 2006). We coupled IL­2 with IL­2 mAb (referred to as 
IL­2 complexes or IL­2 C hereafter) and examined the effects 
on NK cells and other lymphocytes during EAE. During our 
initial experiments, we developed an injection regimen of 
frequency and dosage that conferred maximal expansion and 
IL-2–mAb complexes expand NK cells with a unique phenotype
Our data using NK cell–depleting antibodies and Cx3cr1/ 
mice show the inhibitory function of NK cells against auto­
immune responses within the CNS. An alternative approach 
to investigate the role of NK cells in this process is to enrich 
these cells in vivo. Prior studies have shown that anti–IL­2 
mAbs (clone S4B6) guide IL­2 toward cells with intermediate­
Figure 4. IL-2 complexes attenuate EAE and silence Th17 cell responses in the CNS. (A) Effect of IL-2 complexes on the development and progres-
sion of EAE. n = 12–16/group. Data are pooled from three independent experiments. P < 0.01 between days 9 and 21 and P < 0.05 between days 22 and 30 
(Mann-Whitney U test). (B and C) Effects of IL-2 complexes on the development and progression of EAE in mice that received anti-NK1.1 mAb (B; n = 8/group)  
or in Cx3cr1/ mice (C; n = 8–12/group). Data are pooled from two independent experiments. Error bars represent the means ± SEM. P > 0.05 for any time 
point (Mann-Whitney U test). (D) Cellular infiltration (top) and demyelination (bottom) were analyzed using CNS sections harvested from days 12–20 after 
immunization. Bars, 100 µm. (E) Visualization and quantification of brain inflammation by in vivo bioluminescence imaging at day 15 after immunization.  
(F) In vivo MRI brain images of mice treated with IgG or IL-2 complexes (IL-2 C) showed a decrease in inflammation and demyelination in IL-2 complex–treated 
mice. Focal lesions (arrows) were located around the lateral ventricle in IgG-treated mice and increased signal intensity on T2-weighted lesions, which were 
attenuated in IL-2 complex–treated mice. Data from D–F are representative of two independent experiments (n = 4–6/group). Error bars represent the  
means ± SEM. P-values were determined by a Student’s t test. (G) Lymphoid or CNS cells were restimulated with MOG overnight, and IFN-– and IL-17– 
expressing CD4+ T cells were measured by intracellular staining. (H and I) qRT-PCR of IFN- and IL-17 transcripts from sorted CD4+ T cells. Data from G–I are 
representative of four independent experiments (n = 6–12/group). Error bars represent the means ± SEM. P-values were determined by a Student’s t test.
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CNS-resident NK cells inhibit EAE in the presence  
of IL-2 complexes
We evaluated the impact of IL­2 complexes on the clinical 
course of EAE. Compared with control mice, the onset of 
EAE in treated mice was delayed and neurological deficits 
were relatively mild (Fig. 4 A). Accordingly, these mice also ex­
hibited attenuated cellular infiltrates and demyelination (Fig. 4, 
D–F). While assessing the influence of IL­2 complexes on 
MOG­reactive Th cell responses, we found that IL­17 mRNA 
expression and protein production by lymph node cells were 
not significantly altered by IL­2 complexes, whereas IL­17 
production by CD4+ T cells in the CNS was dramatically re­
duced (Fig. 4, G–I). IFN­–producing CD4+ T cells within 
the CNS were also reduced (Fig. 4 G). Alterations for CD8+ 
T cell–derived IFN­ and IL­17 were minimal (Fig. S4).
maintenance of NK cells, with its associated disease protec­
tion (Table S1 and not depicted). Using this protocol, we 
showed that IL­2 complexes were more efficient than IL­2 
or anti–IL­2 mAb alone in expanding NK cells, both in the 
lymph nodes and the CNS (Fig. 3 A). With regard to their 
phenotypic characteristics, NK cells from IL­2 complex–
treated mice exhibited no dramatic alterations in the expres­
sion of NKG2D, Ly49D, CD244 (2B4), Ly49A, and Ly49C 
(not depicted), a significant up­regulation of the inhibitory 
receptor NKG2A on NK cells in the CNS (Fig. 3 B), and an 
intact capacity to produce IFN­ (Fig. 3 C). IL­2 complexes 
also increased the numbers of CD8+ T cells with a predomi­
nantly memory phenotype and a concurrent decrease in CD4+ 
T cells. CD4+CD25+ T cells and NKT cells were also increased 
at varying degrees (Fig. S5).
Figure 5. Effects of NK cells on the capacity of microglia and other CNS-derived APCs to promote myelin-reactive T cell proliferation and 
Th17 responses. (A) Proliferation of naive CD62Lhigh MOG35-55-specific CD4+ transgenic 2D2 T cells cultured with microglia, astrocytes (AS), mDCs, pDCs, 
CD11b+CD45+, or irradiated CD4 splenocytes from MOG-primed mice at the peak of EAE disease at an APC/T cell ratio of 5:1, in the presence or absence of 
10 µg/ml MOG35-55 peptide. Mice were treated with control IgG or anti-NK1.1 before immunization. Results are expressed as the changes in counts per  
minute (CPM). Irradiated CD4 splenocytes stimulate 2D2 cells at 2/3 of the capacity of mDCs. (B) Release of IL-17 by T helper cell supernatant from A after 
72 h. (C) Capacity of CNS-derived APCs to drive Th17 cell responses and to be affected by NK cells. Naive (CD25CD62LhighCD44low) CD4+ T cells were sorted 
from lymph nodes and spleens of 2D2 transgenic mice. Subsequently, 2 × 105 cells of the indicated APC types and NK cells (all isolated from the CNS)  
were added to the culture. NK cells from the IL-2 complex–treated mice were injected into the brain. Il-17a transcripts were quantified by qRT-PCR. Data in  
A–C are representative of two independent experiments using cells from 15–20 mice/group. MG, microglia. Error bars represent the means ± SEM. P-values 
were determined by an ANOVA test. (D) Interactions between NK cells and microglia influence myelin-reactive Th17 cells in vivo and the importance of the 
NKG2A–Qa1 pathway. Naive (CD25CD62LhighCD44low) CD4+ T cells were sorted from lymph nodes and spleens of 2D2 mice. Subsequently, 2 × 105 cells 
were injected i.v. into MOG/CFA/PT-primed RAG1/c/ mice. Simultaneously, the same numbers of microglia from Cx3cr1+/ (MG+/) and Cx3cr1/ 
(MG/) mice and NK cells from the IL-2 complex–treated mice were injected into the brain as previously described (Cardona et al., 2006b). STAT3 phos-
phorylation was quantified by FACS and compared in mice receiving CD4+ T cells alone or mice that also received microglia from Cx3cr1+/ or Cx3cr1/ 
mice. RNA was isolated from 2D2 CD4+ cells and Ror, Ror (also know as Rorc), and Il-17a transcripts were quantified by qRT-PCR. Data represent three 
experiments with 15–22 mice per group each. Error bars represent the means ± SEM. P-values wre determined by an ANOVA test. For C and D, + and  
 denote culture with or without NK cells.
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that myeloid DCs (mDCs) presenting endogenous myelin 
peptides preferentially polarize CD4+ T cells toward the 
Th17 cell lineage in a relapsing remitting EAE model (Bailey 
et al., 2007). We therefore compared the capacity of microglia 
and several types of APCs from the CNS, either migrated to 
this location or resident in the CNS, in priming 2D2 MOG­
specific T cells. In agreement with Bailey et al. (2007), mDCs 
were most potent among the CNS­derived APCs, includ­
ing microglia, astrocytes, plasmacytoid DCs (pDCs), and 
CD11b+CD45+ cells (microglia and macrophages), in induc­
ing 2D2 T cell proliferation (Fig. 5 A) and production of IL­17 
(Fig. 5 B) in mice with EAE. It is of note that when these 
APCs were isolated from MOG/CFA­primed mice that also 
received anti­NK1.1 mAb, their capacity to induce 2D2 cell 
proliferation and production of IL­17 was increased (Fig. 5, 
A and B). Interestingly, microglia emerged as the most potent 
APCs in driving Th17 cells, despite their capacity to induce 
2D2 cell proliferation at levels comparable to those of mDCs 
(Fig. 5, A and B). Similar results were obtained using APCs 
from Cx3cr1/ mice (in which homing of NK cells to the 
CNS is severely impaired; unpublished data).
Given that NK cells alter the cytokine microenvironment 
in the CNS (Fig. S3) and that the best defined factors that 
determine Th cell subset differentiation are cytokines and 
chemokines that are present at the initiation stage of T cell re­
ceptor ligation (O’Garra, 1998), we compared the capacity of 
the CNS­derived APC to release Th17 cell–polarizing cyto­
kines and determined whether this process could be altered by 
NK cells. Similar amounts of IL­1, IL­6, and IL­23 were pro­
duced by microglia and mDCs from control mice with EAE 
(unpublished data). Importantly, production of these cyto­
kines was dramatically enhanced in microglia and, to a lesser 
extent, mDCs when NK cells were depleted (not depicted) or 
failed to home to the CNS (Table I). In contrast, the differ­
ences for TGF­1 and IL­21 release by microglia and mDCs 
were not significant (unpublished data). Blocking experiments 
indeed confirmed the importance of IL­1 and IL­6 for the ca­
pacity of microglia to prime Th17 cells (unpublished data).
To investigate the mechanism by which NK cells could 
influence the capacity of APCs to support Th17 cell differen­
tiation, we cultured naive 2D2 CD62Lhigh cells with mDCs, 
pDCs, CD8+ DCs, or astrocytes in the presence or absence 
of NK cells. We found that these APCs, isolated from NK 
cell–depleted or Cx3cr1/ mice, exhibited varied capacity 
To assess whether NK cells mediated the protection 
against EAE during IL­2 complex therapy, we depleted NK 
cells before EAE induction and IL­2 complex treatment. Re­
moval of NK cells almost completely abolished the therapeu­
tic effects of IL­2 complexes (Fig. 4 B). Because anti­NK1.1 
mAbs remove NK cells from both periphery and CNS, we 
asked whether NK cells in the periphery, the CNS, or both 
contributed to the protective effects of IL­2 complexes on 
EAE. For this purpose, we treated Cx3cr1/ mice with IL­2 
complexes upon EAE induction. The clinical features of EAE 
were nearly identical in Cx3cr1/ mice that received con­
trol IgG or IL­2 complexes (Fig. 4 C). Injection of anti­
NK1.1 mAb into the brain eliminated NK cells from the CNS 
without altering peripheral NK cells and largely abrogated 
the therapeutic effect of IL­2 complexes (unpublished data). 
Thus, we conclude that the effects of IL­2 complexes on EAE 
depend on CNS­resident NK cells.
In dissecting potential contributions of other IL­2R– 
bearing cells, we treated CD1d/ mice (Mendiratta et al., 
1997; devoid of NKT cells), CD8/ mice, and mice depleted 
of CD25+ cells with IL­2 complexes before EAE induction. 
IL­2 complex injection attenuated EAE in CD1d/ mice 
and mice depleted of CD25+ cells (Fig. S6, A and B). The 
magnitude of the disease attenuation in these mice was simi­
lar to that observed in WT B6 mice (Fig. 4 A). IL­2 complexes 
partially lost their effectiveness against EAE in CD8/ mice 
(Fig. S6 C). Furthermore, unlike NK cells (see Fig. 6 A) CD8+ 
T cells did not reside in close proximity with microglia. CD8+ 
T cells were capable of killing microglia, albeit much less effec­
tively than NK cells (unpublished data). Collectively, these data 
indicated that NKT cells, T reg cells, and CD8+ T cells do not 
contribute in a significant manner to the EAE phenotype in 
mice receiving IL­2 complexes.
NK cells condition the cytokine microenvironment in the CNS
Our finding that modulation of NK cells affects myelin­ 
reactive Th17 cells in the CNS suggested that NK cells can 
influence the cytokine environment in a different manner in 
the CNS and in the periphery. To test this possibility, we com­
pared the cytokine profile in these two anatomical compart­
ments. Lymph node culture supernatants, brain, and spinal cord 
homogenates from MOG­immunized mice that received anti­ 
NK1.1 mAb or from MOG­immunized Cx3cr1/ mice had a 
tendency for an increased expression of the Th17­polarizing 
cytokines IL­1, IL­6, TGF­1, and TNF, as well as the pro­
inflammatory chemokines MCP­1, MIP­1, and MCP­1, 
as compared with controls. We observed the opposite in mice 
treated with IL­2 complexes, and such alterations appeared 
to be milder in lymph nodes (Fig. S3).
NK cells suppress the induction of Th17 transcription 
factors by microglia
Our observation that NK cell–mediated inhibition of CNS 
inflammation and Th17 cell responses are restricted to the 
CNS suggested the involvement of additional players specific 
to the CNS. Previous studies have elegantly demonstrated 
Table I. Microglia are a major source of Th17-polarizing 
cytokines in the absence of NK cells
Cytokines Cell source
Microglia mDCs Astrocytes
IL-1 283.5 ± 9.0** 151.4 ±19.8 40.0 ± 3.9
IL-6 478.3 ± 49.7* 139.1 ±16.3 48.0 ± 6.3
IL-23 233.5 ± 21.7** 91.7 ± 12.5 81.3 ± 12.5
Microglia, mDCs, and astrocytes were isolated from CNS tissues, and cytokine 
release was measured by ELISA. n = 4/group. Data represent three independent 
experiments. *, P < 0.05; **, P < 0.01, Student’s t test.
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or failed to home to the CNS (Table I), we hypothesized that 
the interactions between NK cells and microglia determine 
the magnitude of CNS inflammation and myelin­reactive 
Th17 cells. We assessed the capacity of microglia, in the pres­
ence or absence of NK cells, to trans­activate the signature tran­
scription factors of the Th17 cell lineage, ROR, ROR, 
and STAT3 (Bettelli et al., 2006b; Yang et al., 2008; Zhou et al., 
to drive Th17 cell responses (Fig. 5 C). Compared with 
microglia, the impact of these cells was relatively mild, and NK 
cells had a minimal influence on their capacity to impact 
Th17 cell responses (Fig. 5 C). Similar results were obtained 
with prepolarized Th17 cells (unpublished data).
Considering that microglia were the major source of 
Th17 cell–polarizing cytokines when NK cells were depleted 
Figure 6. Reciprocal chemoattraction between NK cells and microglia. (A) Colocalization of NK cells and microglia. Cx3cr1GFP+/ mice were immunized 
with MOG/CFA, brain tissues were harvested during days 12–20 after immunization, and CNS sections were made. NK cells and GFP+ microglia (green) were 
visualized with anti-NK1.1 or -NKp46 (red). Representative images of four independent experiments with four mice per group each are shown. Bar, 10 µm.  
(B, left) MIP-1 release by 2 × 105 NK cells isolated from lymph node (LN) of naive or MOG-challenged mice and from the CNS during the peak of EAE in 
mice. (B, right) MCP-1 release from 2 × 105 CNS-derived APCs isolated during the peak of EAE. Chemokines were detected by ELISA in cell culture supernatant 
of the corresponding cells without stimulation. Results are representative of three similar experiments in which cells from 15–20 perfused donor mice were 
pooled and each APC subset was analyzed three times. Error bars represent the means ± SEM. P-values were determined by an ANOVA test. (C, top) CNS-
infiltrating NK cells recruit microglia in an MIP-1–dependent manner. NK cells induced a substantial recruitment of purified microglia in transwell experi-
ments. Medium only was used as a control. Anti–MIP-1 antibody or MIP-1 was added as indicated. 2 × 105 microglia were added to the upper chamber.  
(C, bottom) Supernatants from microglia recruit NK cells in a MCP-1–dependent manner. Chemotaxis of purified CNS-infiltrating NK cells toward chemokines 
produced by microglia was tested by using a transwell assay. Supernatants collected from purified microglia were stimulated with PMA and were added to 
the lower chambers of transwell plates. Medium only was used as a control. Anti–MCP-1 antibody or MCP-1 was added as indicated. 2 × 105 NK cells were 
added to the upper chamber. Specific migration was calculated as migration index. Bars represent means of triplicate wells from a representative of three 
independent experiments. Error bars represent the means ± SEM. P values were determined by a Student’s t test. (D) Morphological features of microglia and 
their proximity to inflammatory foci when NK cells are manipulated. Cx3cr1GFP+/, Cx3cr1/, and Cx3cr1+/+ mice, with microglia labeled with GFP, were  
immunized with MOG/CFA. A portion of the +/ mice was treated with control IgG, anti-NK1.1 mAb, or IL-2 complexes. Brain tissues were harvested during 
days 12–20 after immunization. Morphological features of microglia in relation to NK cells were analyzed by confocal microscopy. Activated microglia  
(increased size of cell body and thickening of proximal processes) were noted at a higher prevalence in control mice. A significantly higher level of reactive 
oxygen species (ROS; denoting areas of inflammation) was noted in NK cell–deleted mice, whereas the IL-2 complex treatment group had a lower level of ROS 
compared with control mice. Representative images of three independent experiments with four mice per group each are shown. Bars, 10 µm.
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on the physical relationship between these two cell types. 
Colocalization studies revealed that NK cells resided in close 
proximity to microglial cells (Fig. 6 A), whereas such prox­
imity was not evident between NK cells and mDCs, pDCs, 
or astrocytes (not depicted). Furthermore, CNS­derived NK 
cells readily produce MIP­1 (Fig. 6 B). Among mDCs, 
pDCs, astrocytes, and microglia, the latter cells produced 
MCP­1 (Fig. 6 C). Transwell migration and blocking experi­
ments revealed that production of MIP­1 by NK cells and 
MCP­1 by microglia resulted in reciprocal chemoattraction 
of these cells (Fig. 6 C). Additionally, a statistically significant 
increase was observed in the recruitment of NK cells toward 
supernatants from microglia, compared with astrocytes, neu­
rons, and other CNS­infiltrating cells (DCs, T cells, and macro­
phages; unpublished data). In the absence of NK cells in the 
CNS, microglial cells exhibited dramatic activated morphologi­
cal features, whereas the opposite was true when NK cells were 
enriched in the CNS (Fig. 6 D).
Missing self on microglia ablates NK cell tolerance
We assessed the numerical relationship between NK cells and 
microglia. Although the absolute numbers of CNS­resident 
NK cells in mice that received IL­2 complexes were slightly 
higher than in control mice with EAE (Fig. 7 A), the ratio of 
2009), in vivo. For this purpose, we isolated microglia, as well 
as naive or Th17­polarized 2D2 cells (Bettelli et al., 2006a), and 
transferred these cells into RAG1/c/ hosts via intra­
cerebral and intravenous routes, respectively. Microglia 
from Cx3cr1/ mice and, to a lesser extent, Cx3cr1+/ 
mice enhanced IL­17 transcripts, together with increases 
in ROR, ROR, IRF4 transcripts, and STAT3 expression 
levels (Fig. 5 D and not depicted). Cotransfer of NK cells 
derived from CNS tissues largely ablated these effects, and 
this was largely dependent on perforin expression by NK cells 
(Fig. 5 D) because transfer of perforin/ NK cells restored 
the capacity of microglia to promote Th17 cell expansion 
(Fig. 5 D). Additionally, transfer of IFN­/ NK cells resulted 
in a tendency to reduce the effects on microglia (Fig. 5 D). 
In trying to discriminate whether NK cells acted directly on 
Th17 cells or whether microglia acted as intermediary target 
cells, we considered the former possibility less likely because 
CNS­derived NK cells did not effectively lyse Th17 pheno­
type cells (unpublished data).
Reciprocal chemoattraction between NK cells and microglia 
underlies their physical proximity
The preferential impact of NK cells on microglia, among 
several types of CNS­derived APCs, prompted investigations 
Figure 7. Missing self on microglia breaks NK cell toler-
ance. (A and B) Inverse relationship between NK cells and  
microglia. CNS infiltrates were isolated from MOG/CFA-primed 
Cx3cr1 GFP+/ mice after treatment with control IgG, anti-
NK1.1 mAb, or IL-2 complexes. (A) Numbers of NK cells (×105) 
and GFP+ microglia (×106) that were analyzed by FACS. (B) Ratio 
of CNS-resident NK cells and total CNS infiltrates. P < 0.01  
for comparisons of microglial cell numbers from each experi-
mental group with that from control mice. P < 0.01 for com-
parisons of the ratios of CNS-derived NK cells/total infiltrates 
from the groups that received IL-2 C with that from the  
remaining groups. P < 0.05 for comparisons between groups  
of mice that received IgG and groups that received anti-NK1.1, 
or groups of Cx3cr1/ mice. (C) NK cells principally target  
microglia. NK cells were purified from pools of CNS tissues 
harvested from MOG-immunized mice treated with IL-2 com-
plexes. Microglia, astrocytes, mDCs, and pDCs were isolated 
from MOG-primed Cx3cr1+/ mice and incubated with 51Cr. The 
effector (NK) and target (microglia) cells (5 × 104) were incu-
bated at E:T ratios of 25:1 and cytolytic effects were measured 
in a 4-h 51Cr-release assay, as previously described (Shi et al., 
2000). (D) Microglia, astrocytes, and mDCs were isolated from 
MOG-primed Cx3cr1+/ mice or Cx3cr1/ mice and incubated 
with 51Cr. The effector (NK) and target (5 × 104) cells were 
transferred into RAG1/c/ mice and a rapid elimination 
assay (see Materials and methods) was performed. (E) Role of 
the NKG2A–Qa1 pathway in the interaction between NK cells and microglia. Cytotoxicity assay was conducted with effector NK cells from MOG/CFA-
primed WT or perforin-deficient mice. Target cell microglia were isolated from Cx3cr1+/ mice, Qa1/Cx3xr1 double-deficient mice (Qa1/ MG), or with 
microglia overexpressing Qa1 (Qa-1+ MG). MG denotes microglia isolated from MOG/CFA-primed Cx3cr1/ mice. Qa1+MG denotes overexpression of Qa1 
on microglia from Qa1/ mice (see Materials and methods). Data regarding the killing activity of NK cells from the CNS of WT animals with EAE were  
not available, as it was technically challenging to purify sufficient numbers of NK cells to perform the assay. (F) Expression of Qa1 on CNS-derived APCs  
in the presence or absence of NK cells. CNS-derived cells (days 12–20 after immunization) from MOG-immunized mice treated with IgG or anti-NK1.1 
were analyzed for Qa1 expression by FACS. All data are representative of two to three independent experiments with 12–18 mice per group each  
(mean ± SEM). P-values were determined by an ANOVA test.
JEM VOL. 207, August 30, 2010 
Article
1915
protected microglia from NK cell killing (Fig. 7 E) and re­
duced the influence of NK cells on Th17 cells (Fig. 5 D). 
As expression of other types of activating and inhibitory NK 
cell receptors, including NKG2D, Ly49D, CD244 (2B4), 
Ly49A, and Ly49C, was not dramatically altered upon NK 
cell homing to the CNS in control and IL­2 complex–treated 
mice immunized with CFA/MOG (unpublished data), we 
propose that the NKG2A–Qa1 pathway plays a dominant 
role in the interactions between NK cells and microglia.
Biological consequences of NK cell–microglia interactions 
and their dependence on myelin-reactive Th17 cells
Having determined that NK cells suppress the induction of 
Th17 cell–defining transcription factors that are transactivated 
by microglia, we sought to address whether this type of inter­
action between NK cells and microglia can influence the 
expression of EAE in a cotransfer model. During our initial 
experiments, we titrated the numbers of 2D2 transgenic 
T cells, microglia, and NK cells required to induce mild, moder­
ate, and severe EAE in the recipient mice (unpublished data). 
Because augmentation of myelin­reactive Th17 cells by 
microglia is anticipated to exacerbate EAE, we decided to use 
a low number of 2D2 cells to induce mild EAE so that effects 
of microglia and NK cells on the phenotype of EAE in recipi­
ent mice could be easily detected. Transfer of 2D2 cells, along 
with injection of microglia, resulted in a remarkable augmen­
tation of EAE severity (Fig. 8 A). In contrast, addition of NK 
cells largely reversed the effect of microglia, and such reversal 
was abrogated when Qa1 was overexpressed on microglia 
(Fig. 8 A). Furthermore, the effect of NK cells expanded by 
IL­2 complexes was dependent on the presence of perforin 
and, to a lesser extent, IFN­, as perforin­ and, to a lesser ex­
tent, IFN­–deficient NK cells lost their capacity to over­
come the effect of microglia on EAE (unpublished data).
CNS­resident NK cells/total CNS infiltrates was 6­ to 10­fold 
higher in mice that received IL­2 complexes, as compared 
with control mice (Fig. 7 B). The observed inverse relation­
ship between the numbers of NK cells and microglia could 
be merely a reflection of changes in the intensity of CNS in­
flammation when NK cells are reduced or enriched. How­
ever, the physical proximity between NK cells suggested 
direct killing of microglia as an alternative possibility. Indeed, 
among mDCs, pDCs, astrocytes, and microglia, the latter 
cells were principal targets of NK cells in vitro (Fig. 7 C) and 
in vivo (Fig. 7 D), and the efficacy of such elimination was 
abolished when NK cells were isolated from perforin­deficient 
mice (Fig. 7 E).
The lack of killing by perforin­deficient NK cells sug­
gested that NK cells used cytolytic activity toward microglia 
during CNS inflammation. In addition to physical factors, 
loss of the self­MHC class I molecule Qa1 on activated mi­
croglia may render these cells key targets for NK cells. Com­
parisons of expression of Qa1 on APCs from control mice 
with EAE indicated that levels of Qa1 expression were lower 
on microglia than on mDCs, pDCs, and astrocytes (Fig. 7 F). 
Significantly, the differences in Qa1 expression on microglia 
versus other APCs were greater in NK cell–depleted mice 
(Fig. 7 F) and in Cx3cr1/ mice immunized with CFA/
MOG (not depicted). Thus, a physical proximity, as well as a 
reduction in Qa1 expression, ablated NK cell tolerance to 
microglia, whereas other types of APCs were relatively spared 
(as a result of maintained Qa1 expression and a relative dis­
tance from NK cells).
To further investigate the receptor–ligand pathways that 
govern interactions between NK cells and microglia, we used 
two approaches. Qa1 deficiency promoted NK cell killing 
activity (Fig. 7 E) and diminished the effects of microglia on 
Th17 cells (Fig. 5 D). Conversely, overexpression of Qa1 
Figure 8. Interactions between NK cells, 
microglia, and Th17 cells influence the 
expression of EAE. (A) CD4+ T cells were 
sorted from the lymph nodes and spleen of 
2D2 transgenic mice and cultured under con-
ditions for EAE induction (see Materials and 
methods). Subsequently, 2 × 105 cells were 
injected i.v. into MOG/CFA/PT-primed RAG1/ 
c/ mice. Simultaneously, the same num-
bers of microglia from Cx3cr1+/ or Cx3cr1/ 
mice and NK cells from the IL-2 complex–
treated mice were injected into the brain as 
previously described (Cardona et al., 2006b). In some experiments, Qa1 was overexpressed on microglia with a lentiviral vector (see Materials and methods).  
Development of EAE in the recipient mice was monitored and compared. P < 0.05 after day 10 after cell transfer (Mann-Whitney U test) for com-
parisons between groups receiving 2D2 cells versus 2D2 cells with microglia (except for the group receiving Qa1 overexpressing microglia) and for groups 
receiving 2D2 cells with microglia versus 2D2 cells with microglia + NK cells. P > 0.05 (Mann-Whitney U test) at all time points for comparisons among 
the groups of mice receiving 2D2 cells versus 2D2 cells with microglia and NK cells and for groups receiving untransfected versus Qa1-transfected  
microglia. n = 8–12/group. Error bars represent the means ± SEM. (B) Anti-NK1.1 mAb fails to dramatically alter the course of EAE in IL-17–deficient mice. 
WT and IL-17/ mice were immunized with MOG/CFA. Groups of the immunized mice also received anti-NK1.1 mAb or control IgG (see Materials and 
methods) upon immunization. Development of EAE was monitored and compared. P < 0.05 after day 10 (Mann-Whiteney U test) for comparisons be-
tween IL17+/+ mice that received anti-NK1.1 mAb and all of the other groups. P > 0.05 (Mann-Whitney U test) at all time points for comparisons among 
the remaining groups except for IL-17+/+ mice that received anti-NK1.1 mAb. n = 12–15/group. Error bars represent the means ± SEM. Data from A and B 
are pooled from three similar experiments.
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NKG2A–Qa1 interactions appeared to play a central 
role in interactions between NK cells and microglia. In the 
peripheral lymphoid organs, expression of the inhibitory re­
ceptor NKG2A on NK cells is induced by gene products of 
infectious agents, such as cytomegalovirus, and is sustained by 
certain cytokines (i.e., IL­12 and IL­10; Sáez­Borderías et al., 
2009; Lassen et al., 2010). Interestingly, cytomegalovirus was 
found to enhance the expression of HLA­E, the human counter­
part of Qa1 (Tomasec et al., 2000). Factors that affect the expres­
sion of NKG2A on NK cells and Qa1/HLA­E on target cells 
within the CNS are unknown. In addition to the local inflam­
matory milieu, CNS­infiltrating NK cells express high levels 
of nicotinic acetylcholine 2 receptors (unpublished data). 
Whether these receptors for neuronal or glial transistors, together 
with other CNS factors, promote expression of NKG2A 
warrants further investigations.
Activation­induced cell death is an important mechanism to 
contract the T cell compartment in adaptive immune responses. 
Under several pathological conditions, such as infections or trau­
matic injury, NK cells readily home to the brain and spinal cord 
(Shi and Ransohoff, 2009). Innate NK cells participate in early 
host defenses and mobilize the adaptive immune system to com­
bat infectious agents. Once infection is controlled, inflammatory 
responses driven by microglia and other types of CNS­derived 
APCs must be tapered down to avoid autoimmune responses. 
By interacting with MHC class I molecules that are constitu­
tively expressed by microglia during steady state and are lost 
upon prolonged activation, NK cells can ensure tolerance to self 
while allowing toxicity toward stressed cells.
Microglia are prone to activation (Hanisch and Kettenmann, 
2007). Microglia in the CNS are activated in EAE even 
before the arrival of T cells and other types of peripherally 
derived APCs (Ponomarev et al., 2007). Future studies will 
examine whether the temporal activation of microglial cells 
and other CNS­derived APCs underlies their differential 
expression of Qa1 to better explain why microglia become 
targets for NK cells during CNS inflammation.
It must be acknowledged that the precise role of microg­
lia during CNS inflammation is not clear, in part because of 
technical difficulties in enriching these cells from adult brain 
tissues. Microglia are capable of performing APC functions 
upon activation and of priming and inducing final effector 
T cell functions (Ford et al., 1996; Olson and Miller, 2004; 
Ponomarev et al., 2005). Activated microglia are thought to 
play a role in the onset of both MS in humans and EAE in B6 
mice (Ponomarev et al., 2007). However, recent studies have 
provided evidence that microglia are less effective than other 
APCs in the CNS in presenting myelin antigens and in prim­
ing Th cell responses (Bailey et al., 2007). This finding was 
confirmed in the current model (Fig. 5). We also found that 
a lack of suppressive effects of NK cells led to an expanded 
microglia compartment and augmented the capacity of these 
cells to produce Th17­polarizing cytokines, further suggest­
ing our previous observation that CNS­derived APCs, resi­
dent or immigrant, behave differently in the presence or in 
the absence of NK cells.
To further investigate the biological consequences of 
the interactions between CNS­resident NK cells, microglia, 
and autoreactive Th17 cells, we used IL­17/ mice, which are 
relatively resistant to the development of EAE. Depletion of 
NK cells from IL­17/ mice did not significantly alter the 
EAE phenotype of these animals (Fig. 8 B). Similarly, injec­
tion of IL­2 complexes had a minimal effect on the severity 
of EAE in IL­17/ mice (unpublished data). Thus, interac­
tions between NK cells, microglia, and Th17 cells play criti­
cal roles in determining the phenotype of EAE.
DISCUSSION
Compared with other organ systems, the CNS has several 
unique properties with respect to immune responses, which 
includes the spectrum of APCs as well as the neuroimmune 
microenvironment. Regulatory functions of NK cells in 
EAE, MS, and other autoimmune diseases have been pro­
posed, but the exact role of NK cells within the CNS remains 
elusive. Through a combination of approaches using an NK 
cell–depleting antibody and blockade of NK cell homing to 
the CNS via disruption of a chemokine receptor that is criti­
cal for NK cell recruitment and via expansion of NK cells by 
IL­2 complexes, we provide compelling evidence that NK 
cells within the target organ critically control the magnitude 
of local inflammatory and autoimmune responses against 
myelin antigens in the CNS. The findings presented in this 
paper support a dominant role for NK cells in controlling 
autoimmunity in target organs. First, selective blockade of 
NK cell homing to the CNS was sufficient to induce un­
abated pathology in MOG­primed mice. Second, the thera­
peutic effect of IL­2 complexes was almost entirely dependent 
on the NK cells in the CNS. Finally, suppression of myelin­
reactive Th17 cells (and to some extent Th1 cells) by NK cells 
was largely restricted to the CNS compartment. Thus, these 
findings suggest regulatory functions of NK cells within a tar­
get organ of autoimmunity, which appears to be more impor­
tant for disease manifestation than the events that occurred 
in the periphery (Fig. S7).
The finding that NK cells in the CNS play a more critical 
role than NK cells in the periphery during CNS inflamma­
tion strongly suggests the participation of an additional factor 
that is specific to the CNS. These factors might include CNS 
Ags, signals generated from neuronal cells (Tracey, 2009), 
and CNS­derived APCs. APCs present in the CNS, whether 
resident or recruited from the periphery, include CD11c+ 
DCs, mDCs, CD8+ DCs, astrocytes, and microglia (Olson 
and Miller, 2004; Greter et al., 2005; Bailey et al., 2007; 
Weber et al., 2007). Among the different APCs, we found that 
NK cells preferentially interacted with microglia. The physi­
cal proximity of NK cells with microglia, as a result of recip­
rocal chemoattractions, together with colocalization within 
inflammatory foci, promoted interactions between these two 
cell types, and a reduced expression of the MHC class I molecule 
Qa1 on activated microglia triggered NK cell–mediated cyto­
toxicity. Altogether, our data suggest that microglia are key 
targets for NK cells.
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CNS disease. For example, daclizumab targets the human 
IL­2 receptor and inhibits MS and autoimmune uveitis 
disease activities (Rose et al., 2004, 2007; Li et al., 2005; 
Bielekova et al., 2006, 2009; Wynn et al., 2010). The efficacy 
of this drug has been linked to the expansion of CD56bright 
NK cells (Li et al., 2005; Bielekova et al., 2006, 2009). 
Copaxone and Rebif/Avonex (IFNs) also increase NK cell 
cytotoxic activity (Sand et al., 2009; Vandenbark et al., 2009) 
and the prevalence of CD56bright NK cells, respectively. The 
IL­2 complexes used in the current studies not only recapitu­
late the effects of some of these drugs but also provide mech­
anistic inputs on the importance of CNS versus peripheral 
NK cells and the means used by NK cells to protect against 
disease. The importance of CD94/NKG2A­dependent inhi­
bition of myelin­reactive T cells (Lu et al., 2007) and its asso­
ciation with reduced microglia in the CNS during EAE has 
been elegantly demonstrated (Leavenworth et al., 2010). The 
current study extends this mechanistic explanation for 
the contact of NK cells with other types of CNS­derived APCs. 
Altogether, these studies provide novel insight into the 
biology of NK cells in relation to organ­specific autoimmu­
nity and might lead to the design of NK cell–based approaches 
for intervention in inflammatory and autoimmune disorders 
of the CNS.
MATERIALS AND METHODS
Mice. Female C57BL/6 (B6, H­2b) mice were purchased from Taconic, 
and 2D2 mice (Bettelli et al., 2006a) and IL­17/ mice (Komiyama et al., 
2006) were provided by V. Kuchroo (Brigham and Women’s Hospital and 
Harvard Medical School, Boston, MA) and Y. Iwakura (University of Tokyo, 
Tokyo, Japan), respectively. Other mutant mice, including Cx3cr1GFP/GFP 
(Cx3cr1/; Jung et al., 2000), Qa1/, CD1d/, RAG1/c/, 
perforin/, and IFN­/ mice were either available in our colony or pur­
chased from The Jackson Laboratory. All mutant mice were backcrossed 
to the B6 background for 8–12 generations and were housed in pathogen­
free conditions at animal facilities of the Barrow Neurological Institute 
(Phoenix, AZ) or the Tianjin Neurological Institute (Tianjin, China). All 
animal studies were approved by Animal Care and Use Committees of the 
Barrow­St. Joseph and Tianjin Neurological Institute.
EAE model. The mouse peptide autoantigen MOG35­55 (M­E­V­G­W­Y­
R­S­P­F­S­R­V­V­H­L­Y­R­N­G­K) was synthesized (purity > 95%) by 
Bio Synthesis Inc. To induce acute EAE, B6 mice were injected s.c. in the 
hind flank with 200 µg MOG35­55 peptide in CFA (BD) containing 500 µg of 
nonviable dessicated Mycobacterium tuberculosis. On the day of, and 2 d after, 
immunization, the mice were also inoculated with 200 ng pertussis toxin 
(List Biological) i.v. The passive transfer EAE model with 2D2 T cells is de­
tailed in the Fig. 8 legend. In brief, splenocytes from MOG TCR transgenic 
(2D2) mice were stimulated with 10 µg/ml MOG35­55 for 48 h and then ex­
panded in 5 ng/ml IL­2 and IL­7 for 5 d. The lymphoblasts were stimulated 
with 1 µg/ml of plate­bound anti­CD3 and 1 µg/ml of anti­CD28 in the 
presence of 10 ng/ml IL­12 and 25 ng/ml IL­18 for 24 h. Depending on the 
experiments, 2 × 105–106 2D2 T cells were transferred into RAG1/c/ 
mice by i.v. injection. Clinical presentations in both models were assessed as 
previously described (Huang et al., 2006).
In vivo antibody and cytokine administration. mAbs directed against 
mouse NK1.1 (PK136 clone; Koo and Peppard, 1984), IL­2 (S4B6 clone), and 
CD25 (PC61) were produced from hybridomas (American Type Culture Col­
lection). Carrier­free recombinant mouse IL­2 was purchased from eBioscience. 
Mouse IgG2a (Sigma­Aldrich) was used as the isotype control antibody.
NK cell–microglia interactions have a profound impact 
on myelin­reactive Th cells, particularly the Th17 cell subset. 
In vivo cell transfer experiments demonstrated that NK cells 
are capable of abolishing the effects of microglia on the trans­
activation of the Th17 signature transcription factors ROR, 
ROR, and STAT3. It is generally believed that Th cells 
complete their differentiation in draining lymph nodes 
(Banchereau and Steinman, 1998). However, chronic CNS 
inflammation leads to neogenesis of lymphoid structures 
within the CNS (Magliozzi et al., 2007), which may serve as 
a structural basis for continued T helper cell differentiation 
and expansion in this compartment. Participation of microg­
lia clearly indicates that differentiation of autoreactive Th17 
cells in the CNS is substantially different from Th17 cell dif­
ferentiation in the peripheral lymphoid compartment. The 
importance of NK cell–microglial cell interactions in disease ex­
pression during IL­2 complex therapy is illustrated by our cell 
transfer experiments. Our finding that neither anti­NK1.1 mAbs 
nor IL­2 complexes significantly altered the course of EAE in 
IL­17/ mice further indicates that myelin­reactive Th17 cells 
are the ultimate targets influenced by interactions between NK 
cells and microglial cells during CNS inflammation (Fig. 8 B).
NK cells, as well as microglia, have been frequently shown 
to induce neurotoxicity (Cardona et al., 2006a,b; Hanisch and 
Kettenmann, 2007). One study has suggested that microglial 
neurotoxicity is accelerated by the absence of CX3CR1 
(Cardona et al., 2006b). Whether lack of CX3CR1 expression, 
caused by a lack of NK cell recruitment, is responsible for 
unabated neurotoxicity is unclear. MOG­primed Cx3cr1/ 
mice exhibited similar disease phenotype to mice depleted of 
NK cells, suggesting that a lack of NK cells in the CNS, rather 
than microglial neurotoxicity, is responsible for the disease pheno­
type. The temporal, spatial, and specific microenvironment of 
the CNS and the local cytokine milieu may further influence the 
detrimental or beneficial effects of NK cells and microglia.
In addition to NK cells, other IL­2R–bearing cells, including 
NKT cells, CD4+CD25+Foxp3+ regulatory T cells, and CD8+ 
T cells with a memory phenotype, are also expanded, at various 
degrees, by IL­2 complexes. Thus, they might as well contribute 
to disease protection. Although the regulatory functions of CD8+ 
T cells are less well characterized than those of T reg cells and 
NKT cells, emerging evidence indicates that a subpopulation of 
CD8+ T cells can suppress CD4+ T cells (Lu et al., 2008), and 
mice lacking this CD8+ T cell population can develop exagger­
ated immune responses to autoantigens (Hu et al., 2004). These 
cells recognize Qa1 and might use similar mechanisms to NK 
cells to suppress the functions of microglia (and/or other CNS­
derived APCs) or CD4+ T cells, as previously suggested (Lu 
et al., 2008). Indeed, in our system the IL­2–expanded CD8+  
T cells also lysed microglia, albeit at lower efficiency than 
NK cells, and IL­2 complexes partially lost their therapeutic 
effects in CD8/ mice. Whether and how these CD8+ T cells 
act on other CNS­derived APCs or myelin­reactive T cells 
directly or indirectly warrants further investigations.
Finally, our findings have important implications for 
understanding the efficacy of some drugs currently used in 
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between the 30–70% percoll interface was collected as the CNS mononu­
clear cells for staining. APCs (mDC, CD45hiCD3CD11b+F4/80+CD11c+; 
pDC, CD11bCD11c+B220+PDCA­1+CD8+ or CD8 and CD11bC
D11c+B220CD8+CD205+ or CD205CD8+ DCs; astrocytes, GFAP) 
were isolated and enriched as previously described with modification (Bailey 
et al., 2007; Liu et al., 2007). For cytokine induction, the isolated CNS­ 
derived APCs were cultured with 3 ng/ml GM­CSF (R&D Systems). 1 µg/ml 
of soluble CD40L (R&D Systems) was added. After 48 h, IL­1, IL­6, IL­21, 
TGF­, and IL­23 in the supernatant was assayed by ELISA according to the 
manufacturer’s instructions (eBioscience).
Microglial cell isolation. We used mice in which the CX3CR1 gene was re­
placed with a cDNA encoding GFP, such that Cx3cr1+/ (Cx3cr1+/GFP) mice 
express the GFP reporter in cells that retain their receptor function, whereas 
Cx3cr1/ (Cx3cr1GFP/GFP) cells are also labeled and lack CX3CR1 expression 
(Cardona et al., 2006a,b). Because CX3CR1­GFP reporter mice can exclusively 
identify microglia in vivo in the CNS, the Cx3cr1+/ mice permitted us to iso­
late and purify these cells ex vivo (Cardona et al., 2006a,b). Before removal of 
CNS tissues, perfusion was routinely performed to exclude contamination of 
peripherally arrived cells also expressing CX3CR1 (also GFP+).
Construction of lentiviral vectors encoding Qa-1 and transduction 
into microglia. Full­length Qa­1 cDNA was amplified by RT­PCR from 
RNA isolated from splenocytes of B6 mice. After verification of the 
sequence, cDNA was ligated into the Plvx­DsRed­Monomer­C1 vector 
(Takara Bio Inc.) replacing the red protein coding sequence of DsRed. The 
recombinant lentivirus was produced by Lenti­X 293T Cells (Takara Bio 
Inc.) with Lenti­X HT Packaging System (Takara Bio Inc.). Virus was col­
lected 72 h after transfection and titers were up to 5–8 × 108 infectious 
units/ml. Microglia purified from B6 background Qa­1–deficient mice were 
infected with virus in 24­well plates precoated with 20 µg/ml poly­L­lysine 
for 16 h. The virus­containing transduction medium was then replaced with 
fresh growth medium, the incubation of the cells continued for 24 h at 37°C 
and 5% CO2.
NK cell cytotoxicity assays. NK cell cytotoxicity was assessed by the 
chromium release assay using 51Cr­labeled YAC­1 mouse lymphoma cell line, 
microglia, and other types of APCs (Shi et al., 2000). Freshly purified NK 
cells were incubated with 51Cr­labeled target cells (5 × 103) at various effector 
cell/target cell ratios. After 4 h of incubation, the supernatants were harvested 
and 51Cr release was measured with a  counter (PerkinElmer). The percent­
age of specific lysis was calculated according to the following formula: (ex­
perimental release  spontaneous release)/(maximum release  spontaneous 
release) × 100. Cytotoxicity assay was done in triplicate (Shi et al., 2000).
A rapid elimination assay was used to determine whether NK cells can 
eliminate microglia in vivo, as previously described (Assarsson et al., 2004). 
5 × 105 51Cr­labeled microglia were microinjected into the brain of the re­
cipient mice. The CNS tissues (brain and spinal cord) were removed after 
8 h and counted in a gamma radiation counter. The percentage of remain­
ing radioactivity was determined as follows: (organ  background/dose of 
cells  background) × 100. Radioactivity recovered from control mice and 
experimental mice was an accurate measurement of intact microglia remain­
ing in the CNS.
Cell migration assay. Chemotaxis of microglia toward chemokines pro­
duced by CNS­derived NK cells was tested in vitro using a polycarbonate 
filter microchamber filtration system (Neuro Probe) with small pores (3 µm). 
2 × 105 microglial cells were added to the upper well of the upper compart­
ment in the presence of 1 nM PMA. The lower compartment was filled with 
300 µl of medium containing no chemotactic supplement, recombinant 
10 ng/ml MIP­1 (R&D Systems), or supernatants collected from purified 
microglia cells stimulated for 24 h with 1 nM PMA with or without 5 µg/m 
of anti–MIP­1 (R&D Systems). Chemotaxis of CNS­derived NK cells to­
ward chemokines produced by microglia was tested using the same system. 
In brief, 2 × 105 NK cells were seeded into the upper compartment of the 
For depletion of NK1.1+ cells or CD25+ cells in vivo, 100 µg of anti­
NK1.1 mAb or anti­CD25 mAb was injected i.p. into each mouse at day 2 
after immunization. Every 5 d thereafter, 50 µg anti­NK1.1 mAb or anti­
CD25 were injected i.p. until termination of experiments (Shi et al., 2000; 
Liu et al., 2005). Depletion of NK1.1+ and CD25+ cells was confirmed by 
flow cytometry and was always >90%.
For the preparation and administration of IL­2 and anti–IL­2 mAb 
complexes (referred to as IL­2 complexes), equal volumes of 30 µg/ml rIL­2 
and 300 µg/ml of anti–mouse IL­2 mAb in PBS were mixed in vitro and 
100 µl of this solution was injected i.p. into each mouse, resulting in IL­2 
complexes formed by 1.5 µg rIL­2 with 15 µg of anti–IL­2 mAb per mouse, 
as modified from a published protocol (Boyman et al., 2006). As controls, 
animals were treated with rIL­2 or anti–IL­2 mAb only and received 200 µl 
IgG with the same amount of either rIL­2 or anti–IL­2 mAb as for the IL­2 
complexes. Additional control mice received equivalent doses of purified 
normal rat isotype IgG2a. Injections were repeated two times every week 
starting on the same day of MOG35­55 immunization (day 0) until termina­
tion of the experiment.
Intracerebral injection. Mice were anesthetized with 87 mg/kg ketamine and 
13 mg/kg xylazine and placed in the stereotaxic apparatus (Kopf Instruments). 
Microglia injection was performed as previously described (Cardona et al., 
2006b). Implantation was performed as previously described with some modifi­
cations (see Supplemental material; Abizaid et al., 2006; Hemsley et al., 2009).
Neuropathology and neuroimaging. For study of inflammation, GFP+ 
microglia morphology, cellular colocalization, and dihydroethidium (DHE) 
oxidation in mice brain, mice received DHE i.p. and were sacrificed by 
pentobarbital injection 18 h later and perfused by intracardiac puncture with 
50 ml of cold PBS. Brains and spinal cords were removed, frozen immedi­
ately, and then stored at 80°C. 10–30­µm serial cryosections were prepared. 
Three serial sections were stained with H&E, luxol blue, PE anti­NK1.1 
(PK136), or anti­NKp46 (29A1.4) antibodies. All images were captured with 
a confocal microscope (LSM 710; Carl Zeiss, Inc.) with Microscope image 
acquisition software.
For imaging of ROS generation in brain, bioluminescence images in 
live mice were captured using the Xenogen IVIS200 imager (Caliper Life 
Sciences) at several time points after injection of 27 mg/kg DHE (Invitro­
gen). A region of interest tool was used to measure the fluorescent intensity. 
Data were collected as photons per second per centimeter squared using the 
Living Image software (Caliper Life Sciences).
MRI was performed using a 7T small animal, 30­cm horizontal­bore 
magnet, and BioSpec Avance III spectrometer (Bruker) with a 116­mm high 
power gradient set (600 mT/m) and a 72­mm whole­body mouse transmit/
surface receive coil configuration. Axial and coronal T1­weighted (MSME; 
echo time [TE] 10.5 ms, repetition time [TR] 322 ms, 0.5­mm slice thick­
ness, matrix 256 × 256, field of view [FOV] 2.8 cm, eight averages, 40 coro­
nal slices, scan time 22 min, and 20 axial slices, scan time 16 min) and 
fat­suppressed turbo spin echo T2­weighted (RARE; TE1 14.5 ms, TE2 
65.5 ms, TR 4,500 ms, 0.5­mm slice thickness, Matrix 256 × 256, FOV 2.8 
cm, eight averages, 40 coronal slices, scan time 28 min, and 20 axial slices, 
scan time 28 min) images were acquired, covering the volume of brain from 
the olfactory bulb/frontal lobe fissure to the cervical spinal cord. MRI data 
were analyzed using the MEDx3.4.3 software package (Medical Numerics) 
on a LINUX workstation.
Isolation of mononuclear cells from the CNS. For CNS­infiltrating 
mononuclear cell isolation, at day 11 after EAE induction mice were sacri­
ficed and perfused with PBS delivered transcardially to eliminate contami­
nating blood cells in the CNS. Fresh brain and/or spinal cords were removed 
from five to six mice, cut into small pieces, and digested in 10 mM Hepes/
NaOH buffer containing 1 mg/ml collagenase for 1 h at 37°C. Tissues were 
homogenized with a syringe, filtered through a 70­µM cell strainer to obtain 
a single cell suspension, and centrifuged. Cell pellets were resuspended 
in 30% percoll and centrifuged against 70% percoll. The cell monolayer 
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kit (QIAGEN), in accordance with the manufacturer’s instructions. The 
following primers were used: IL­17 forward, 5­CCTCCAGAATGT­
GAAGGTCA­3; IL­17 reverse, 5­CTATCAGGGTCTTCATTGCG­3; 
IFN­ forward, 5­AGCTCTTCCTCATGGCTGTT­3; IFN­ reverse, 
5­TTTGCCAGTTCCTCCAGATA­3; ROR forward, 5­TCTCCCT­
GCGCTCTCCGCAC­3; ROR reverse, 5­TCCACAGATCTTGCAT­
GGA­3; ROR forward, 5­ CCCCCTGCCCAGAAACACT­3; ROR 
reverse, 5­GGATGCCCCCATTCACTTACTTCT­3; hypoxanthine­ 
guanine phosphoribosyltransferase (HPRT) forward, 5­AGCCTAAGATGAG­
CGCAAGT­3; and HPRT reverse, 5­TTACTAGGCAGATGGCCACA­3. 
The HPRT gene was amplified and served as an endogenous control. 1 µl 
of first­strand cDNA product was amplified with platinum Taq polymerase 
(Invitrogen) and gene­specific primer pairs. Each sample was assayed in triplicate 
and experiments were repeated twice. The relative amounts of mRNA were 
calculated by plotting the Ct (cycle number), and mean relative expression was 
determined by the 2Ct comparative method.
Online supplemental material. Fig. S1 shows approaches to study NK 
cells during CNS inflammation. Fig. S2 shows the effect of anti­NK1.1 mAb 
on the development and progression of EAE in B6 mice and in CD1d/ 
mice. Fig. S3 shows global alteration of Th17­polarizing cytokines and other 
inflammatory mediators in mice when NK cells are manipulated. Fig. S4 shows 
the impact of anti­NK1.1 mAb or IL­2 C injection on CD8+ T cell responses. 
Fig. S5 shows effects of IL­2 immune complexes on NK (CD3NK1.1+), 
NKT (CD3+NK1.1+), CD4+, CD4+CD25+, and CD4+CD25+T cells. 
Fig. S6 shows the contributions of IL­2 receptor–bearing NKT cells, 
T reg cells, and CD8+ cells to protection against EAE conferred by IL­2 
complexes. Fig. S7 shows NK cell–mediated inhibition of Th17 cells and 
autoimmunity in the CNS. Table S1 shows the effects of IL­2 complexes on 
induction and maintenance of NK cells, as well as clinical features of 
EAE. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20092749/DC1.
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